Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.91
+6.4%
$2.67
$1.29
$7.12
$10.00M2.19113,850 shs16,417 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.28
+0.6%
$0.31
$0.22
$4.79
$11.77M-0.211.74 million shs55,605 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.41
-0.2%
$0.57
$0.25
$3.65
$14.92M1.54.55 million shs787,965 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$1.76
+1.7%
$2.41
$1.61
$10.45
$2.98M-0.15343,552 shs3,511 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-3.24%-19.37%-34.67%-32.20%-23.50%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-1.22%-4.11%-10.52%-35.21%-89.99%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+4.63%+7.39%-39.66%-40.97%-82.75%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-3.35%-4.95%-54.47%-77.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$1.91
+6.4%
$2.67
$1.29
$7.12
$10.00M2.19113,850 shs16,417 shs
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
$0.28
+0.6%
$0.31
$0.22
$4.79
$11.77M-0.211.74 million shs55,605 shs
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
$0.41
-0.2%
$0.57
$0.25
$3.65
$14.92M1.54.55 million shs787,965 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$1.76
+1.7%
$2.41
$1.61
$10.45
$2.98M-0.15343,552 shs3,511 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-3.24%-19.37%-34.67%-32.20%-23.50%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-1.22%-4.11%-10.52%-35.21%-89.99%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
+4.63%+7.39%-39.66%-40.97%-82.75%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-3.35%-4.95%-54.47%-77.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00
N/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
2.00
Hold$3.381,088.38% Upside
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
3.00
Buy$4.00885.22% Upside
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest QLGN, LPTX, IMCC, and MBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
8/27/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
6/18/2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.44M0.25N/AN/A$1.03 per share1.85
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/A$0.91 per shareN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/A$1.77 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/A($4.12) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$67.56M-$1.58N/AN/AN/AN/A-237.65%-155.38%11/12/2025 (Estimated)
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%11/14/2025 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$6.26MN/A0.00N/AN/AN/A-202.16%11/12/2025 (Estimated)

Latest QLGN, LPTX, IMCC, and MBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
-$0.29-$0.40-$0.11-$0.40N/AN/A
8/14/2025Q2 2025
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A-$1.00N/A-$1.00N/AN/A
8/12/2025Q2 2025
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 million
8/12/2025Q2 2025
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
-$0.39-$0.49-$0.10-$0.49N/AN/A
7/21/2025Q1 2025
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A-$1.82N/A-$1.82N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/AN/AN/AN/AN/A
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.32
0.72
0.62
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
N/A
1.34
1.34
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
N/A
1.15
1.15
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.71
0.71

Institutional Ownership

CompanyInstitutional Ownership
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
30.46%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
15.52%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%

Insider Ownership

CompanyInsider Ownership
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
7.50%
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2.10%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
1.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3405.25 millionN/ANot Optionable
Leap Therapeutics, Inc. stock logo
LPTX
Leap Therapeutics
4041.44 million38.33 millionOptionable
Moleculin Biotech, Inc. stock logo
MBRX
Moleculin Biotech
2036.74 million29.65 millionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.70 million1.66 millionNot Optionable

Recent News About These Companies

Qualigen Granted New Patents Covering 25 Countries
Qualigen Therapeutics, Inc. (QLGN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$1.90 +0.12 (+6.42%)
As of 10:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Leap Therapeutics stock logo

Leap Therapeutics NASDAQ:LPTX

$0.28 +0.00 (+0.57%)
As of 10:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Moleculin Biotech stock logo

Moleculin Biotech NASDAQ:MBRX

$0.41 0.00 (-0.25%)
As of 10:25 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$1.76 +0.03 (+1.73%)
As of 10:20 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.